Real estate companies such as Unitech, Peninsula Land, HDIL and Future Capital, the financial services arm of Future Group, are in talks with investors including some leading private equity funds for raising investments for their projects, after the collapse of Lehman Brothers, whose third party fund had promised investments in these property companies' projects, according to industry sources.
The group's testing lab chain SRL Ranbaxy has been renamed as Religare Super Laboratories. RanAir, its charter aviation company will be known as Religare Voyages. About 15 group companies, including joint ventures like Religare Macquarie Private Wealth, Religare Aegon and Vistaar Religare have come under the umbrella brand Religare.
Companies like Shanta Biotech, Panacea Biotec and Serum Institute of India are among the leading vaccine makers which have not been able to file any fresh application to the WHO due to this temporary de-recognition of the country's drug regulatory system. The WHO pre-qualification is essential for companies to supply vaccines to national immunisation programmes funded by the WHO or UNICEF outside the country.
Hospitals and medical research organisations that conduct clinical trials on humans may soon face surprise inspections from the regulatory authorities. The hospitals, the sponsor pharma companies and the institutional ethics committees that oversee these trials will all come under the regulator's scanner.
Recently, IT czar Azim Premji bought a 10 per cent stake in Subhiksha through his personal investment arm for nearly Rs 230 crore, valuing the retailer at Rs 2,300 crore. Premji's firm purchased this stake from ICICI Venture. However, this time around, Subhiksha promoters are expected to issue fresh equity to investors and expect the valuation to be around Rs 3,800 crore, sources said.
Data on clinical trials of genetically-modified brinjal have been made public by the Genetic Engineering Approval Committee of the environment ministry.
The group, which employs nearly 26,000 employees, plans to cut employee costs by one per cent, or Rs 65 crore (Rs 650 million), in the current year by redeploying people in its various businesses and reducing new hirings. "Instead of external hiring, we have redeployed a part of our people resources from our mature businesses to the new ventures," Future Group CEO Kishore Biyani said.
The WHO feels that the practice is not only against international ethics, but also increases the risk of wrong medication. INNs are names that help to identify the chemical composition of a pharmaceutical substance without having to use long and unwieldy chemical names.
Several Indian states including Himachal Pradesh, Delhi, Goa, Madhya Pradesh and Bihar are offering their hospitals to the private sector to manage. This has elicited immediate positive reactions from private sector hospital chains - among them Fortis Healthcare, Apollo Hospitals and Wockhardt Hospitals.
Firm reaches out-of-court agreement on 5 of 19 patent challenges in the US.
Companies that earlier took 36 months on housing projects are now completing them in around 30 months by boosting efficiencies and using modern technology. Commercial project developers are going a step further, completing projects in 17 months instead of 24. In some instances, mainly in smaller commercial buildings, developers are trying to cut down the project completion time to a mere 9 months.
Caisse manages nearly $155 billion of pension and insurance funds in Canada and North America while Ivanhoe has 70 shopping centres in Canada, the US, Europe and Latin America, totalling 46 million sq ft.
The regulator has also cancelled the licences of three packagers providing services to Subhiksha for violating the packaging rules. The warehouses are based in Bhiwandi, which is on the outskirts of Mumbai.
While the government expects the new urea policy to bring more investment, the fertiliser industry is less than enthused. New capacities to make urea, industry representatives say, will come up only if adequate fuel and timely payment of subsidy dues is ensured.
Medicine prices in India are set to go up by 1-2 per cent as the National Pharmaceutical Pricing Authority has decided to permit companies to factor in the rising packaging and processing costs into the retail price. The panel will notify the revised three costs -- for conversion, packaging and packing material -- shortly. The norms were finalised last week after a six-month-long analysis of the market.
With China expected to reopen several hundred bulk drug units after the Olympics, prices of some key bulk drugs, including penicillin and paracetamol, have crashed in the Indian market.
Property developers, consultants and brokers have seen a 40 per cent decline in enquiries from home buyers over the last three months.
The drive to cut costs is becoming critical as key input costs - steel, cement and labour - that account for 40 per cent of project costs have escalated 50 per cent over the past year.
The recent pullout by ICICI Venture and Citigroup Venture from a three-year-old drug discovery partnership with Dr Reddy's Laboratories points to angel investors' growing aversion to risk in pharma and biotech firms, say experts.
Unitech, the country's second-largest property developer, is planning to raise nearly $1 billion (Rs 4,200 crore) in the current financial year from private equity players for its hotel, commercial and retail projects across the country.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances